Stifel initiated coverage on Custom Health Holdings (TSX:CHLT) with a Buy rating, setting a C$12 price target and highlighting potential upside to C$18. The thesis centers on its pill-dispensing platform addressing a costly healthcare problem. Overall, the note is modestly constructive for CHLT given the supportive valuation setup rather than new reported fundamentals.
Stifel initiated coverage on Custom Health Holdings (TSX:CHLT) with a Buy rating, setting a C$12 price target and highlighting potential upside to C$18. The thesis centers on its pill-dispensing platform addressing a costly healthcare problem. Overall, the note is modestly constructive for CHLT given the supportive valuation setup rather than new reported fundamentals.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
